Fisher Paykel Healthcare | FPH

Fisher Paykel Healthcare traded at 19.88 this Wednesday June 29th, decreasing 0.22 or 1.09 percent since the previous trading session. Looking back, over the last four weeks, Fisher Paykel Healthcare lost 1.34 percent. Over the last 12 months, its price fell by 36.12 percent. Looking ahead, we forecast Fisher Paykel Healthcare to be priced at 19.35 by the end of this quarter and at 18.24 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
19.88
Daily Change
-1.09%
Yearly
-36.12%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Auckland International Airport 7.38 0.02 0.27% 1.51%
Ansell 22.50 -0.40 -1.75% -48.29%
A2 Milk 4.94 -0.07 -1.40% -23.29%
Cochlear 198.61 -3.67 -1.81% -21.08%
CSL 270.74 -3.29 -1.20% -5.07%
EBOS 39.40 -0.91 -2.26% 21.98%
Fisher Paykel Healthcare 19.88 -0.22 -1.09% -36.12%
Healius Ltd 3.68 -0.02 -0.54% -20.52%
Nanosonics Ltd 3.43 -0.09 -2.56% -41.57%
Ramsay Health Care 73.42 -0.13 -0.18% 16.63%
ResMed 30.81 0.06 0.20% -5.95%
Sonic Healthcare 32.86 -0.29 -0.87% -14.43%
Skycity Entertainment 2.95 0.11 3.87% -15.95%
Synlait Milk Ltd 3.22 0.07 2.22% -11.54%
Somnomed Ltd 1.25 0.04 3.31% -43.44%

Indexes Price Day Year
NZX 50 10959 -59.81 -0.54% -13.40%

Fisher Paykel Healthcare
Fisher & Paykel Healthcare Corporation Limited designs, manufactures and markets medical device products and systems for use in respiratory care, acute care, surgery and the treatment of obstructive sleep apnea. The Company’s segment includes North America, which includes all activities controlled by entities or employees based in the United States and Canada; Europe, which includes all activities controlled by entities or employees based in the United Kingdom, France, Germany, Sweden, Turkey and Russia, and Asia-Pacific, which includes all activities controlled by entities or employees based in Australia, Japan, India, China, South Korea, Taiwan and Hong Kong, and Other segment includes New Zealand, Latin America, Africa, the Middle East and other countries.